- |||||||||| Prolia (denosumab) / Amgen
Review, Journal: Diagnosis and Current Treatment of Aneurysmal Bone Cysts. (Pubmed Central) - Mar 7, 2024
Selective arterial embolization has significantly contributed to the development of effective treatments for these situations. Embolization or radiation, as well as denosumab therapy, are widely used as therapies for ABCs in anatomic locations where surgery would significantly increase morbidity.
- |||||||||| Prolia (denosumab) / Amgen
A 3D model of breast cancer-bone metastasis to mimic dysregulation of bone remodeling and drug response (Section 6) - Mar 5, 2024 - Abstract #AACR2024AACR_9718;
Embolization or radiation, as well as denosumab therapy, are widely used as therapies for ABCs in anatomic locations where surgery would significantly increase morbidity. Denosumab and zoledronic acid were selected as they are standard treatments for reducing bone loss in patients, and were used to treat the model at 30
- |||||||||| Prolia (denosumab) / Amgen
In vitro assays for investigating the effects of cancer therapeutics on bone (Section 13) - Mar 5, 2024 - Abstract #AACR2024AACR_6004;
Denosumab was added in the cultures at day 0, and tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) activity was measured from the culture medium collected at day 7...BMP-2 and E2 stimulated osteoblast differentiation and activity indicated by the increase in ALP activity, PINP and calcium levels. We conclude that these culture systems can be used for studying the effects of cancer therapeutics and identifying new potential compounds affecting the disease process of bone metastases with different mechanisms of action.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Cancer treatment-induced bone loss. (Pubmed Central) - Mar 5, 2024
Currently, there are no bone anabolic therapies for patients with cancer. Appropriate therapies are necessary to maintain optimal bone health, particularly in patients at heightened risk.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Sustained hypophosphatemia after denosumab in a patient on hemodialysis. (Pubmed Central) - Mar 5, 2024
The potential role of compromised phosphate absorption versus increased deposition will be discussed. We recommend a cautious approach to dmab therapy in patients on dialysis, with evaluation of bone turnover and serum phosphate levels prior to initiation of treatment.
- |||||||||| Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment closed: Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI (clinicaltrials.gov) - Mar 4, 2024
P4, N=40, Active, not recruiting,
We recommend a cautious approach to dmab therapy in patients on dialysis, with evaluation of bone turnover and serum phosphate levels prior to initiation of treatment. Recruiting --> Active, not recruiting
- |||||||||| Prolia (denosumab) / Amgen
Journal: Treatment of Osteoporosis after Hip Fracture: Survey of the Korean Hip Society. (Pubmed Central) - Feb 29, 2024
Denosumab was the most commonly used first-line treatment option for osteoporosis in hip fracture patients...The results of this study that surveyed orthopedic hip surgeons showed that most participants followed the current strategy for management of osteoporosis. Because the end result of osteoporosis is a bone fracture, active involvement of orthopedic surgeons is important in treating this condition.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Awareness of Medication-Related Osteonecrosis of the Jaws Amongst Patients on Antiresorptive and Antiangiogenic Medications. (Pubmed Central) - Feb 26, 2024
It primarily affects individuals undergoing treatment with antiresorptive and antiangiogenic medications, such as bisphosphonates and denosumab, commonly prescribed for osteoporosis and cancer-related bone metastases...Conclusion Notably, a small percentage of participants demonstrated awareness of this condition, indicating a need for continued education and awareness campaigns. Further research and interventions may be warranted to address the specific needs of different age groups and educational backgrounds in promoting safe and effective medication management.
- |||||||||| Prolia (denosumab) / Amgen
Journal: RANKL inhibition reduces lesional cellularity and G?s variant expression and enables osteogenic maturation in fibrous dysplasia. (Pubmed Central) - Feb 25, 2024
P2
The results from this study demonstrated that, in addition to its expected antiosteoclastic effect, denosumab reduces FD lesion activity by decreasing FD cell proliferation and increasing osteogenic maturation, leading to increased bone formation within lesions. These findings highlight the unappreciated role of cellular crosstalk between osteoclasts and preosteoblasts/osteoblasts as a driver of FD pathology and demonstrate a novel mechanism of action of denosumab in the treatment of bone disease.TRIAL REGISTRATION: ClinicalTrials.gov NCT03571191.
- |||||||||| Prolia (denosumab) / Amgen, Tagrisso (osimertinib) / AstraZeneca
Review, Journal, Monotherapy: Could MRONJ Be Related to Osimertinib Monotherapy in Lung Cancer Patients after Denosumab Suspension? (Pubmed Central) - Feb 23, 2024
Our case is a further report that could be intended as an alert both for oncologists and dentists to share decisions about the oral management of such patients together, also informing them about this possible risk. Also, this report could trigger in the scientific community the necessity to evaluate further guidelines for similar doubtful cases in which the drug interaction, the mono-suspension, and the possible removable prosthesis-related additional trauma should be considered causes or con-causes.
- |||||||||| Prolia (denosumab) / Amgen, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Coronavirus-19 (COVID-19) and Hypercalcemic Crisis: A Rare Case Report (San Diego Convention Center, Area L (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3347;
Case Presentation: A 91-year-old female, with no co-morbidities, diagnosed with COVID-19 four days earlier and treated with Ritonavir and Nirmatrelvir (Paxlovid), was referred from a nursing facility due to sudden altered mentation and hypotension...The patient was treated with subcutaneous calcitonin, subcutaneous Denosumab, and IV fluids, resulting in improved mentation and overall clinical status within 48 hours...Potential pathogenic mechanisms include virus-induced calcium channel alterations and dysregulated immunity through cytokine storm, disrupting calcium homeostasis. We recommend prompt recognition and management of hypercalcemia in COVID-19 as well as the involvement of relevant subspecialties to prevent fatal outcomes.
- |||||||||| Prolia (denosumab) / Amgen
Giant Cell Tumor of Bone with H3F3A Mutation and Unusual Bone Formation; Features to Separate from Low-Grade Central Osteosarcoma (Exhibit Hall; Poster Board Number: 80) - Feb 18, 2024 - Abstract #USCAP2024USCAP_1193;
GCT-UBF generally exhibits separate fragments of non-lacelike woven bone, mild to moderate cellularity, rare to absent osteoclast-type giant cells or mitoses, H3F3A mutation and flat copy number changes, with lack of significant atypia, necrosis, additional pathogenic gene alterations or MDM2 amplification, distinguishing these from LG-OSA. A small subset with atypical features and multiple copy number alterations raise concern for malignancy and require further study.
- |||||||||| Prolia (denosumab) / Amgen
Trial completion date: Denosumab for Smoldering Multiple Myeloma (clinicaltrials.gov) - Feb 15, 2024
P2, N=20, Active, not recruiting,
A small subset with atypical features and multiple copy number alterations raise concern for malignancy and require further study. Trial completion date: Jun 2024 --> Jun 2025
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis. (Pubmed Central) - Feb 13, 2024
Several sensitivity analyses also demonstrated similar results of lower diabetes risk associated with denosumab treatment. The results from this cohort study indicating that denosumab treatment was associated with lower risk of incident diabetes may help physicians choose an appropriate antiosteoporosis medication for patients with osteoporosis while also considering the risk of diabetes.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer. (Pubmed Central) - Feb 10, 2024
Therefore, managing patients with prostate cancer that has spread to the bones often involves using bone-targeted medications like bisphosphonates and denosumab to enhance bone structure and minimize skeletal complications...The analysis included details such as patient recruitment, prior palliative therapies, baseline characteristics, follow-up, and outcome reporting. The goal was to highlight the advancements and trends in bone metastasis research in prostate cancer over the past decade, with the aim of developing strategies to prevent and treat bone metastases and improve the quality of life and survival rates for prostate cancer patients.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Clinical application of bone turnover markers in osteoporosis. (Pubmed Central) - Feb 8, 2024
This review describes how BTM can be used for treatment monitoring, including monitoring during discontinuation of alendronate and denosumab therapy. In addition, sources of errors and pitfalls when using BTM monitoring will be described.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Hypercalcemia: a practical review (Pubmed Central) - Feb 7, 2024
The chosen treatments and their speed of introduction depend mainly on the severity of hypercalcemia. They include intravenous rehydration, and antiresorptive agents such as bisphosphonates, denosumab or calcitonin.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Journal: Using Denosumab as a Nonsurgical Management of Aneurysmal Bone Cysts in the Pelvis. (Pubmed Central) - Feb 6, 2024
Denosumab may provide a reliable option in the nonsurgical treatment of ABCs of pelvic origin with expected lower morbidity than the surgical solution and tolerable complications. Further studies on the safety profile and long-term effects of denosumab especially in skeletally immature patients are required.
- |||||||||| Prolia (denosumab) / Amgen
Trial completion, Trial completion date, Trial primary completion date: Bisphosphonates for Prevention of Post-Denosumab Bone Loss (clinicaltrials.gov) - Feb 5, 2024
P2, N=27, Completed,
The double-layer soft tissue suture closure technique can achieve good clinical results in patients with MRONJ of the mandible using anti-bone-resorptive drugs alone, and can provide clinical treatment ideas for MRONJ patients with more complicated drug use. Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jun 2023 | Trial primary completion date: Jan 2024 --> Jun 2023
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal: Metabolic bone diseases : what's new in 2023 (Pubmed Central) - Feb 1, 2024
New meta-analyses confirm the benefits of Vitamin D on fractures and falls. Finally, multiples trials with new molecules for the treatment of rare bone diseases, including osteogenesis imperfecta, fibrous dysplasia and hypoparathyroidism, shown promising results.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, IO biomarker: Immune modulation with RANKL blockade through denosumab treatment in patients with cancer. (Pubmed Central) - Jan 26, 2024
We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, Verzenio (abemaciclib) / Eli Lilly
Observational data, Retrospective data, Journal: Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4/6 Inhibitors in Breast Cancer. (Pubmed Central) - Jan 26, 2024
The differences were statistically significant in the patients who used abemaciclib. Given that the use of this combination is very common in routine clinical practice, it would be advisable to carry out larger prospective studies to clarify the risk of this association.
|
